Loading stock data…
Bolt Biotherapeutics (BOLT)
$3.90-0.37 (-8.66%)
Market ClosedLast close Jun 29
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bolt Biotherapeutics, Inc. in the Healthcare sector is trading at $3.90 with a market capitalization of $9M. Wall Street consensus targets $41.00 (2 analysts), implying a +949.9% move over the next 12 months. The stock is currently near its 52-week low of $3.75, remaining 23.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +949.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26,000↓ | $2.50M↑ | $2.17M↑ | $1.80M↑ | $1.22M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.60M↓ | -$5.61M↑ | -$7.70M↑ | -$9.21M↑ | -$12.12M |
| Net Income | -$7.24M↓ | -$6.63M↑ | -$7.14M↑ | -$8.56M↑ | -$11.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.65M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.23%
Volume
Today's trading volume
79,141
Recent News
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot
BOLT) on Thursday reported a loss of $6.6 million in its fourth quarter. The Redwood City, California-based company said it had a loss of $3.84 per share. The company posted revenue of $2.5 million in the period.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot
BOLT) on Wednesday reported a loss of $7.1 million in its third quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of $3.72. The results exceeded Wall Street expectations.